TNFRSF10B and neoplasm: Upon intravenous (i.v.)injection every three days into mice bearing colorectal cancer xenografts, Liu et al. [48] verified a reduction of tumor growth without systemic toxicity through the decoration of NLC co-delivering irinotecan prodrug (2 mg/kg) and quercetin (2 mg/kg) with conatumumab/AMG 655 (anti-DR5 mAb).